A Phase-II, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Cardiovascular Events in Patients With Prostate Cancer and Cardiovascular Risk Factors Receiving Degarelix or GnRH Agonist
试验速览
- 阶段
- 2 期
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- time to first cardiovascular event
研究概览
简要总结
The purpose of this study is to test if the use of Degarelix for 1 year associated with a lower rate of cardiovascular toxicity compared to Gonadotropin-releasing hormone (GnRH) agonists in patients with advanced prostate cancer and cardiovascular risk factors, receiving combination therapy of Androgen deprivation therapy (ADT) and second line hormonal or chemotherapy?
详细描述
Study design: Randomized phase-2, open label superiority study of the use of ADT combined with second line hormonal or chemotherapy in men with advanced prostate cancer and pre-existing cardiovascular risks.
Study population: Subjects with pre-existing cardiovascular risk with locally advanced or metastatic prostate cancer and scheduled to start ADT in combination with either second line hormonal or chemotherapy. We will exclude patients with use of ADT 6 months prior to randomization.
Intervention- Two initial loading doses of 120mg Degarelix for 1 month followed by 80mg monthly for eleven additional months.
Control- GnRH agonist at the discretion of the treating Urologist/Oncologist for 1 year.
Study Time line- The intervention phase will be for one year. During this year, follow-up visits will occur every 3 months. At each visit, we will assess the occurrence of cardiac-related events. In addition, Protein-specific Antigen (PSA) test will be performed each visit. At baseline, 3, 6 and 12 months cardiac biomarkers and lab measurements will be taken. Echocardiogram will be performed at baseline, 6, 9 and 12 months. In addition, cardio-vascular related events and hospitalizations will be monitored for additional 5 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Locally advanced high-risk prostate cancer OR metastatic prostate cancer patients.
- •Patients are scheduled to receive a combination of either
- •primary ADT for 12 months + either chemotherapy with docetaxel OR
- •primary ADT for 12 months + second line hormonal treatment with abiraterone/ enzalutamide/ apalutamide
- •Patients with a medical history of either of the following:
- •Myocardial infarction
- •Ischaemic or haemorrhagic cerebrovascular conditions
- •Arterial embolic and thrombotic events
- •Ischaemic heart disease
- •Prior coronary artery or iliofemoral artery revascularization (percutaneous or surgical procedures)
- •Peripheral vascular disease (e.g. significant stenosis (ABPI<0.9), claudication, prior vascular surgery/intervention(
- •Two out of three cardiovascular risk factors: hypertension, diabetes, current smoking.
- •Patients age 18-90 years.
- •Life expectancy of over 12 months.
- •WHO performance status of 0-2
- •Subject is able and has agreed to sign a consent form.
排除标准
- •Prior use of ADT in past 6 months prior to randomization. We will, however, allow prior use of anti-androgens such as Casodex, Chimax, Drogenil, and Cyprostat.
- •Known allergic reaction to Degarelix.
- •Any psychological, familial, sociological or geographical situation potentially hampering compliance with the study protocol and follow-up schedule.
研究组 & 干预措施
Degarelix
GnRH Antagonist
干预措施: Degarelix (Drug)
GnRH-agonist
GnRH Agonist
干预措施: GnRH agonist (Drug)
结局指标
主要结局
time to first cardiovascular event
时间窗: 1 year
To compare time to first cardiovascular event as estimated by the cumulated probability at the 1-year time-point of patients with advanced prostate cancer treated for one year with Degarelix vs. GnRH agonist. This will be a composite outcome composed of: Death, CVA, MI, TIA, cardiac emergency room visits, heart catheterization.
次要结局
- time to first MACCE event(1 year)
- cardiac echocardiography(1 year)
- Hormonal Profile(1 year)
- NTproBNP levels(1 year)
- Adverse events(1 year)
- BMI(1 year)
- Quality of life: FACT-P questionnaire(1 year)
- Glucose profile(1 year)
- Cholesterol levles(1 year)
- PSA levles(1 year)